Cervical cancer could become one of the first cancers in the world to be eliminated, with Australia at the forefront of this effort. According to BBC reporting, the latest research and public health data suggest Australia could achieve the official elimination threshold—fewer than 4 cases per 100,000 people—by as early as 2035, and possibly even earlier.
This progress is the result of long-term, systematic prevention strategies. Since 2007, Australia has been a global pioneer in rolling out a national human papillomavirus (HPV) vaccination programme, later expanded in 2013 to include boys in order to break transmission chains. The vaccine, developed by Australian scientists, is regarded as a major breakthrough in global public health.
At the same time, Australia reformed its screening system in 2017, replacing traditional Pap smears with more sensitive HPV testing and extending screening intervals to five years. The government also introduced self-collection testing, significantly improving participation rates, particularly among women with limited access to healthcare or discomfort with traditional examinations.
As a result of these combined measures, cervical cancer incidence and mortality in Australia have halved since the 1980s. In 2021, the country recorded its first-ever case of zero diagnoses among women under 25. Current incidence stands at around 6.3 cases per 100,000 women, with vaccination coverage exceeding 80%.
However, experts warn that progress is uneven. Aboriginal and Torres Strait Islander women continue to experience significantly higher rates of infection and mortality, largely due to reduced access to healthcare and delayed screening. Their elimination timeline is expected to lag more than a decade behind the national average.
Despite these challenges, the Australian model has been recognised by the World Health Organization as a global benchmark. Countries such as Sweden, the United Kingdom, and Rwanda have also set elimination targets, though many continue to face declining vaccination uptake and resource constraints.
Commentary
While Australia’s progress in eliminating cervical cancer appears highly encouraging, several structural risks remain. Post-COVID vaccine hesitancy, rising healthcare costs, and missed school-based vaccinations due to absenteeism could all weaken long-term prevention efforts. These challenges highlight the need for stronger school-level vaccination campaigns and more systematic public health education to prevent coverage rates from slipping as social conditions change.
More importantly, this goal should not be seen merely as a success story for a handful of wealthy countries. It represents a global public good. The international community still needs sustained funding and policy advocacy to encourage more countries—especially low- and middle-income nations—to prioritise HPV vaccination as part of essential public health strategy.